Código QR (código de barras bidimensional)

Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event

There are very few therapeutic options to treat patients with locally advanced or metastatic Urothelial Cancer (UC). Enfortumab vedotin (EV) was recently approved by the FDA and has become a new therapeutic option for patients previously managed with conventional treatments. Despite its efficacy, EV...

ver descrição completa

Na minha lista:
Principais autores: Astha Koolwal Kapoor, Carleton S. Ellis, Deepali Pandey, Derek B. Allison, Zin W. Myint
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-02-01
coleção:Frontiers in Oncology
Assuntos:
diabetes ketoacidosis
CRRT
insulin
enfortumab vedotin
maculopapular rash
liver failure
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2024.1332478/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados